---
layout: default
title: Tranexamic Acid
description: "Tranexamic Acid çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 1 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 181
evidence_level: L5
indication_count: 1
---

# Tranexamic Acid

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>1</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Tranexamic Acidï¼šå¾æ­¢è¡€åŠ‘åˆ°é–‰ç¶“æ²»ç™‚

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Tranexamic Acid å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Tranexamic acid (æ–·è¡€ç‚) åŸæœ¬ç”¨æ–¼å…¨èº«åŠå±€éƒ¨å‡ºè¡€æˆ–å‡ºè¡€æ€§ç–¾ç—…ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**é–‰ç¶“ (amenorrhea)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **2 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | å…¨èº«åŠå±€éƒ¨å‡ºè¡€æˆ–å‡ºè¡€æ€§ç–¾ç—… |
| é æ¸¬æ–°é©æ‡‰ç—‡ | é–‰ç¶“ (amenorrhea) |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.19% |
| è­‰æ“šç­‰ç´š | å¾…è©•ä¼° |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 135 å¼µ |
| å»ºè­°æ±ºç­– | Needs Further Investigation |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Tranexamic acid æ˜¯ä¸€ç¨®æŠ—çº–æº¶è—¥ç‰©ï¼Œé€éæŠ‘åˆ¶çº–ç¶­è›‹ç™½æº¶è§£ä¾†é”åˆ°æ­¢è¡€æ•ˆæœã€‚å…¶åœ¨å©¦ç§‘é ˜åŸŸçš„æ‡‰ç”¨åŒ…æ‹¬ï¼š

1. **æœˆç¶“éå¤šæ²»ç™‚**ï¼šå·²è¢«è­‰å¯¦å¯æ¸›å°‘ 40-60% çš„æœˆç¶“å‡ºè¡€é‡
2. **è¡€æ¶²æƒ¡æ€§è…«ç˜¤æ‚£è€…çš„æœˆç¶“ç®¡ç†**ï¼šç”¨æ–¼é é˜²å’ŒæŠ‘åˆ¶åŒ–ç™‚æœŸé–“çš„æœˆç¶“å‡ºè¡€
3. **èˆ‡è·çˆ¾è’™ç™‚æ³•ä½µç”¨**ï¼šå¯ä½œç‚ºæœˆç¶“æŠ‘åˆ¶ç­–ç•¥çš„ä¸€éƒ¨åˆ†

ç„¶è€Œï¼Œéœ€è¦æ³¨æ„çš„æ˜¯ï¼Œé–‰ç¶“é€šå¸¸æŒ‡æœˆç¶“çš„ç¼ºå¤±ï¼Œè€Œééœ€è¦æ­¢è¡€æ²»ç™‚ã€‚æ­¤é æ¸¬å¯èƒ½åæ˜ çš„æ˜¯åœ¨éœ€è¦æœˆç¶“èª¿æ§æƒ…å¢ƒä¸‹çš„é–“æ¥é—œè¯ã€‚

## è‡¨åºŠè©¦é©—è­‰æ“š

ç›®å‰ç„¡é‡å°é–‰ç¶“é©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ã€‚

## æ–‡ç»è­‰æ“š

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [21701432](https://pubmed.ncbi.nlm.nih.gov/21701432/) | 2011 | Review | Menopause | è¨è«–ç•°å¸¸å­å®®å‡ºè¡€çš„è—¥ç‰©æ²»ç™‚ï¼ŒåŒ…æ‹¬ Tranexamic acid å¯æ¸›å°‘ 40-60% æœˆç¶“å‡ºè¡€é‡ |
| [39043214](https://pubmed.ncbi.nlm.nih.gov/39043214/) | 2024 | Review | J Oncol Pharm Pract | ç³»çµ±æ€§æ¢è¨è¡€æ¶²æƒ¡æ€§è…«ç˜¤å¥³æ€§æ‚£è€…çš„æœˆç¶“é é˜²èˆ‡æŠ‘åˆ¶ç­–ç•¥ |

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å…§è¡›è—¥è£½å­—ç¬¬015392è™Ÿ | æ–·è¡€ç‚è† å›Š | è† å›ŠåŠ‘ | å…¨èº«åŠå±€éƒ¨å‡ºè¡€æˆ–å‡ºè¡€æ€§ç–¾ç—… |
| è¡›ç½²è—¥è£½å­—ç¬¬014441è™Ÿ | è¼”èƒ½é”æ³¨å°„æ¶²5% | æ³¨å°„åŠ‘ | å…¨èº«åŠå±€éƒ¨å‡ºè¡€æˆ–å‡ºè¡€æ€§ç–¾ç—… |
| è¡›ç½²è—¥è£½å­—ç¬¬023242è™Ÿ | "å—å…‰" æ­¢è¡€æ˜æ³¨å°„æ¶² | æ³¨å°„åŠ‘ | å…¨èº«åŠå±€éƒ¨å‡ºè¡€æˆ–å‡ºè¡€æ€§ç–¾ç—… |

## å®‰å…¨æ€§è€ƒé‡

- **è¡€æ “é¢¨éšª**ï¼šèˆ‡é›Œæ¿€ç´ é¡è—¥ç‰©ä½µç”¨æ™‚éœ€ç‰¹åˆ¥æ³¨æ„
- **ä¸»è¦äº¤äº’ä½œç”¨ (Major)**ï¼š
  - Ethinylestradiolã€Estradiolã€Conjugated estrogensï¼ˆå¢åŠ è¡€æ “é¢¨éšªï¼‰
  - Drospirenoneã€Levonorgestrelã€Norethisteroneï¼ˆå£æœé¿å­•è—¥æˆåˆ†ï¼‰
  - Anti-inhibitor coagulant complexã€Factor IX Complex
  - Tamoxifenã€Raloxifeneã€Toremifeneï¼ˆé¸æ“‡æ€§é›Œæ¿€ç´ å—é«”èª¿ç¯€åŠ‘ï¼‰
- **ä¸­åº¦äº¤äº’ä½œç”¨ (Moderate)**ï¼šAlteplaseã€Streptokinaseã€Urokinaseï¼ˆçº–æº¶é…¶åŸæ´»åŒ–åŠ‘ï¼‰
- **ç¦å¿Œç—‡**ï¼šæ´»å‹•æ€§è¡€æ “æ “å¡ç–¾ç—…


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Color Vision Defects** ğŸŸ¡ Moderate
- Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a ...

**Seizures** ğŸŸ¡ Moderate
- Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is ...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal i...

**Disseminated Intravascular Coagulation** ğŸŸ¢ Minor
- The use of tranexamic acid is contraindicated in patients with active intravascular clotting.

**Subarachnoid Hemorrhage** ğŸŸ¢ Minor
- The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šNeeds Further Investigation**

**ç†ç”±ï¼š**
é›–ç„¶ Tranexamic acid åœ¨æœˆç¶“éå¤šæ²»ç™‚ä¸­æœ‰æ˜ç¢ºç™‚æ•ˆï¼Œä½†å…¶èˆ‡é–‰ç¶“çš„é—œè¯æ€§éœ€è¦é€²ä¸€æ­¥é‡æ¸…ã€‚ç›®å‰æ–‡ç»è­‰æ“šä¸»è¦é›†ä¸­åœ¨æœˆç¶“æŠ‘åˆ¶è€Œéé–‰ç¶“æ²»ç™‚ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é‡æ¸…é–‰ç¶“é©æ‡‰ç—‡çš„è‡¨åºŠå®šç¾©èˆ‡æ²»ç™‚ç›®æ¨™
- è©•ä¼°åœ¨ç‰¹å®šè‡¨åºŠæƒ…å¢ƒï¼ˆå¦‚åŒ–ç™‚ç›¸é—œæœˆç¶“ç®¡ç†ï¼‰ä¸­çš„æ‡‰ç”¨
- è€ƒé‡è¡€æ “é¢¨éšªèˆ‡è·çˆ¾è’™ç™‚æ³•ä½µç”¨çš„å®‰å…¨æ€§


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Pemetrexed]({{ "/drugs/pemetrexed/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cephalexin]({{ "/drugs/cephalexin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Polyethylene Glycol 400]({{ "/drugs/polyethylene_glycol_400/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Aspirin]({{ "/drugs/aspirin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cefmetazole]({{ "/drugs/cefmetazole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Tranexamic Acidè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/tranexamic_acid/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_tranexamic_acid,
  title = {Tranexamic Acidè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/tranexamic_acid/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
